Clinical response to sorafenib. (A) BM biopsy of patient AML1, showing predominance of blasts before sorafenib treatment (left), and return of normal hematopoietic activity after treatment at nCRi (right). Nikon Eclipse E800M; eyepiece 10×; objective 40×; numerical aperture of objective lens 0.95; camera Nikon DS cooled camera head DS-5MC & DC camera control unit DS-L2: magnification of picture 400×; software for imaging processing; Adobe Photoshop CS5 Extended Version 12.0.4x32. Similar responses were seen in another 11 patients (supplemental Figure 1; original magnification ×400). (B) MS at the central line entrance site in patient AML1 before sorafenib (i) completely resolved after sorafenib treatment for 3 weeks (ii). In patient AML13, a left breast MS (iii) also completely resolved after sorafenib treatment for 3 weeks (iv). (C) Donor and recipient DNA chimerism for patient AML3 who relapsed after HSCT. Red arrows indicated donor and blue arrows recipient specific allele peaks. A progressive decrease of recipient and a corresponding increase in donor DNA chimerism accompanied clinical responses to sorafenib treatment.